Do analysts prefer PBYI or KLRS?

Kalaris Therapeutics has a consensus target price of $15.60, suggesting a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Do analysts rate KLRS or INDP?

Kalaris Therapeutics presently has a consensus price target of $15.60, indicating a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kalaris Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, KLRS or INDP?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A

Is KLRS or INDP more profitable?

Kalaris Therapeutics' return on equity of -72.78% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -72.78% -43.49% Indaptus Therapeutics N/A -1,030.07% -299.69%

Which has better valuation & earnings, ANL or KLRS?

Adlai Nortye has higher revenue and earnings than Kalaris Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 75.92 -$35.53M N/A N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A

Is ANL or KLRS more profitable?

Adlai Nortye's return on equity of 0.00% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Kalaris Therapeutics N/A -72.78% -43.49%

Kalaris Therapeutics (KLRS) Competitors

$4.75 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.81 +0.06 (+1.26%)

As of 07/2/2026 04:13 PM Eastern

Compare

KLRS vs. ENTA, PBYI, INDP, ANL, and XFOR

Should you buy Kalaris Therapeutics stock or one of its competitors? MarketBeat compares Kalaris Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kalaris Therapeutics include Enanta Pharmaceuticals (ENTA), Puma Biotechnology (PBYI), Indaptus Therapeutics (INDP), Adlai Nortye (ANL), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry.

How does Kalaris Therapeutics compare to Enanta Pharmaceuticals?

Kalaris Therapeutics (NASDAQ:KLRS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Kalaris Therapeutics' average media sentiment score of 0.00 equaled Enanta Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Kalaris Therapeutics	Neutral
Enanta Pharmaceuticals	Neutral

Kalaris Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Kalaris Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kalaris Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Enanta Pharmaceuticals	$65.32M	6.73	-$81.89M	-$2.59	N/A

Kalaris Therapeutics currently has a consensus target price of $15.60, indicating a potential upside of 228.42%. Enanta Pharmaceuticals has a consensus target price of $20.29, indicating a potential upside of 34.25%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kalaris Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Kalaris Therapeutics beats Enanta Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Puma Biotechnology has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Puma Biotechnology has a net margin of 10.69% compared to Kalaris Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

Puma Biotechnology has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$227.18M	1.85	$31.11M	$0.48	17.21
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kalaris Therapeutics has a consensus target price of $15.60, suggesting a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Puma Biotechnology's average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score.

Company	Overall Sentiment
Puma Biotechnology	Neutral
Kalaris Therapeutics	Neutral

Summary

Puma Biotechnology beats Kalaris Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Indaptus Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Kalaris Therapeutics' average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company	Overall Sentiment
Kalaris Therapeutics	Neutral
Indaptus Therapeutics	Neutral

Kalaris Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Kalaris Therapeutics' return on equity of -72.78% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Kalaris Therapeutics presently has a consensus price target of $15.60, indicating a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kalaris Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Summary

Kalaris Therapeutics beats Indaptus Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Adlai Nortye has higher revenue and earnings than Kalaris Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	75.92	-$35.53M	N/A	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Adlai Nortye currently has a consensus price target of $24.25, suggesting a potential upside of 155.53%. Kalaris Therapeutics has a consensus price target of $15.60, suggesting a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Adlai Nortye's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Kalaris Therapeutics	N/A	-72.78%	-43.49%

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Adlai Nortye has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

In the previous week, Adlai Nortye's average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score.

Company	Overall Sentiment
Adlai Nortye	Neutral
Kalaris Therapeutics	Neutral

Summary

Kalaris Therapeutics beats Adlai Nortye on 6 of the 11 factors compared between the two stocks.

How does Kalaris Therapeutics compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

In the previous week, X4 Pharmaceuticals had 5 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 0 mentions for Kalaris Therapeutics. X4 Pharmaceuticals' average media sentiment score of 0.17 beat Kalaris Therapeutics' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
X4 Pharmaceuticals	Neutral
Kalaris Therapeutics	Neutral

Kalaris Therapeutics has lower revenue, but higher earnings than X4 Pharmaceuticals. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$9.01M	43.22	-$79.20M	-$4.54	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

X4 Pharmaceuticals presently has a consensus target price of $9.38, suggesting a potential upside of 127.00%. Kalaris Therapeutics has a consensus target price of $15.60, suggesting a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kalaris Therapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Kalaris Therapeutics' return on equity of -72.78% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

X4 Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Summary

Kalaris Therapeutics beats X4 Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRS vs. The Competition

Export

Metric	Kalaris Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$113.01M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-2.21	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.13	8.66	10.96	6.46
Net Income	-$43.44M	$23.81M	$3.57B	$337.01M
7 Day Performance	9.95%	3.39%	2.12%	1.69%
1 Month Performance	6.98%	10.81%	5.25%	3.81%
1 Year Performance	90.00%	62.61%	33.29%	23.90%

Kalaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRS Kalaris Therapeutics	3.5397 of 5 stars	$4.75 flat	$15.60 +228.4%	+90.0%	$113.01M	N/A	N/A	110	Gap Down
ENTA Enanta Pharmaceuticals	1.4464 of 5 stars	$13.75 +2.2%	$20.29 +47.6%	+91.5%	$400.37M	$65.32M	N/A	160
PBYI Puma Biotechnology	0.8248 of 5 stars	$7.87 +2.5%	N/A	+132.7%	$400.37M	$227.18M	16.39	200	News Coverage Analyst Upgrade Short Interest Increase Lockup Expiration
INDP Indaptus Therapeutics	0.2338 of 5 stars	$3.52 +7.9%	N/A	-70.4%	$399.06M	N/A	N/A	6	Gap Down
ANL Adlai Nortye	1.536 of 5 stars	$9.68 -4.7%	$24.25 +150.5%	+506.0%	$387.36M	$5M	N/A	127

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. ENTA, PBYI, INDP, ANL, and XFOR

How does Kalaris Therapeutics compare to Enanta Pharmaceuticals?

Summary

How does Kalaris Therapeutics compare to Puma Biotechnology?

Summary

How does Kalaris Therapeutics compare to Indaptus Therapeutics?

Summary

How does Kalaris Therapeutics compare to Adlai Nortye?

Summary

How does Kalaris Therapeutics compare to X4 Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. ENTA, PBYI, INDP, ANL, and XFOR

How does Kalaris Therapeutics compare to Enanta Pharmaceuticals?

Does the media favor KLRS or ENTA?

Is KLRS or ENTA more profitable?

Which has more volatility & risk, KLRS or ENTA?

Do institutionals and insiders believe in KLRS or ENTA?

Which has higher earnings & valuation, KLRS or ENTA?

Do analysts rate KLRS or ENTA?

Summary

How does Kalaris Therapeutics compare to Puma Biotechnology?

Which has more risk and volatility, PBYI or KLRS?

Is PBYI or KLRS more profitable?

Which has better valuation and earnings, PBYI or KLRS?

Do institutionals and insiders hold more shares of PBYI or KLRS?

Do analysts prefer PBYI or KLRS?

Does the media refer more to PBYI or KLRS?

Summary

How does Kalaris Therapeutics compare to Indaptus Therapeutics?

Does the media prefer KLRS or INDP?

Which has more risk and volatility, KLRS or INDP?

Is KLRS or INDP more profitable?

Do analysts rate KLRS or INDP?

Do insiders and institutionals believe in KLRS or INDP?

Which has better earnings and valuation, KLRS or INDP?

Summary

How does Kalaris Therapeutics compare to Adlai Nortye?

Which has better valuation & earnings, ANL or KLRS?

Do analysts recommend ANL or KLRS?

Is ANL or KLRS more profitable?

Do institutionals and insiders have more ownership in ANL or KLRS?

Which has more volatility & risk, ANL or KLRS?

Does the media refer more to ANL or KLRS?

Summary

How does Kalaris Therapeutics compare to X4 Pharmaceuticals?

Does the media prefer XFOR or KLRS?

Which has stronger valuation & earnings, XFOR or KLRS?

Do analysts rate XFOR or KLRS?

Do insiders & institutionals hold more shares of XFOR or KLRS?

Is XFOR or KLRS more profitable?

Which has more volatility & risk, XFOR or KLRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools